000 | 01934 a2200517 4500 | ||
---|---|---|---|
005 | 20250516160215.0 | ||
264 | 0 | _c20140210 | |
008 | 201402s 0 0 eng d | ||
022 | _a1815-7920 | ||
024 | 7 |
_a10.5588/ijtld.12.0842 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSanchez-Padilla, E | |
245 | 0 | 0 |
_aMultidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions. _h[electronic resource] |
260 |
_bThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _cAug 2013 |
||
300 |
_a1036-42 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAfrica South of the Sahara _xepidemiology |
650 | 0 | 4 |
_aAntitubercular Agents _xpharmacology |
650 | 0 | 4 | _aCross-Sectional Studies |
650 | 0 | 4 | _aDrug Resistance, Bacterial |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aHIV Infections _xepidemiology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIsoniazid _xpharmacology |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
650 | 0 | 4 | _aPrevalence |
650 | 0 | 4 |
_aRifampin _xpharmacology |
650 | 0 | 4 |
_aTuberculosis _xdrug therapy |
650 | 0 | 4 |
_aTuberculosis, Multidrug-Resistant _xdrug therapy |
650 | 0 | 4 | _aYoung Adult |
700 | 1 | _aArdizzoni, E | |
700 | 1 | _aSauvageot, D | |
700 | 1 | _aAhoua, L | |
700 | 1 | _aMartin, A | |
700 | 1 | _aVaraine, F | |
700 | 1 | _aAdatu-Engwau, F | |
700 | 1 | _aAkeche, G | |
700 | 1 | _aSalaniponi, F | |
700 | 1 | _aBonnet, M | |
773 | 0 |
_tThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease _gvol. 17 _gno. 8 _gp. 1036-42 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.5588/ijtld.12.0842 _zAvailable from publisher's website |
999 |
_c22891959 _d22891959 |